Literature DB >> 34455858

Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis.

Hua Wang1, Ke Chai1, Minghui Du1, Shengfeng Wang2, Jian-Ping Cai3, Yingying Li1, Ping Zeng4, Wanrong Zhu1, Siyan Zhan2,5, Jiefu Yang1.   

Abstract

BACKGROUND: Large-scale and population-based studies of heart failure (HF) incidence and prevalence are scarce in China. The study sought to estimate the prevalence, incidence, and cost of HF in China.
METHODS: We conducted a population-based study using records of 50.0 million individuals ≥25 years old from the national urban employee basic medical insurance from 6 provinces in China in 2017. Incident cases were individuals with a diagnosis of HF (International Classification of Diseases code, and text of diagnosis) in 2017 with a 4-year disease-free period (2013-2016). We calculated standardized rates by applying age standardization to the 2010 Chinese census population.
RESULTS: The age-standardized prevalence and incidence were 1.10% (1.10% among men and women) and 275 per 100 000 person-years (287 among men and 261 among women), respectively, accounting for 12.1 million patients with HF and 3.0 million patients with incident HF ≥25 years old. Both prevalence and incidence increased with increasing age (0.57%, 3.86%, and 7.55% for prevalence and 158, 892, and 1655 per 100 000 person-years for incidence among persons who were 25-64, 65-79, and ≥80 years of age, respectively). The inpatient mean cost per-capita was $4406.8 and the proportion with ≥3 hospitalizations among those hospitalized was 40.5%. The outpatient mean cost per-capita was $892.3.
CONCLUSIONS: HF has placed a considerable burden on health systems in China, and strategies aimed at the prevention and treatment of HF are needed. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: ChiCTR2000029094.

Entities:  

Keywords:  China; cost; heart failure; incidence; prevalence

Mesh:

Year:  2021        PMID: 34455858     DOI: 10.1161/CIRCHEARTFAILURE.121.008406

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  7 in total

1.  Diagnosis for readmission of senile patients hospitalized with acute decompensated heart failure in different departments: a retrospective cross-sectional study.

Authors:  Zhiying Zhao; Wenyan Wang; Jing Jin; Xuemei Liu
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

2.  Development of Core Educational Content for Heart Failure Patients in Transition from Hospital to Home Care: A Delphi Study.

Authors:  Seo-Jin Lee; Bo-Hwan Kim
Journal:  Int J Environ Res Public Health       Date:  2022-05-27       Impact factor: 4.614

3.  Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review.

Authors:  Meiyu Wu; Shuxia Qin; Liting Wang; Chongqing Tan; Ye Peng; Xiaohui Zeng; Xia Luo; Lidan Yi; Xiaomin Wan
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

4.  Quality of Care in Public County Hospitals: A Cross-Sectional Study for Stroke, Pneumonia, and Heart Failure Care in Eastern China.

Authors:  Quan Wang; Li Yang; Jialin Chen; Xi Tu; Qiang Sun; Hui Li
Journal:  Int J Environ Res Public Health       Date:  2022-07-27       Impact factor: 4.614

5.  Identification of potential biomarkers of inflammation-related genes for ischemic cardiomyopathy.

Authors:  Jianru Wang; Shiyang Xie; Yanling Cheng; Xiaohui Li; Jian Chen; Mingjun Zhu
Journal:  Front Cardiovasc Med       Date:  2022-08-23

6.  Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.

Authors:  Yake Lou; Ying Yu; Jinxing Liu; Jing Huang
Journal:  Front Public Health       Date:  2022-08-17

7.  Prevalence and factors associated with cognitive impairment in Chinese heart failure patients: A pilot study.

Authors:  Qi Niu; WeiHua Liu; FengLing Wang; YanHong Dong
Journal:  Front Cardiovasc Med       Date:  2022-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.